IMURAN 25mg price in UAE

Overview

Welcome to Dwaey, specifically on IMURAN 25mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Azathioprine.
IMURAN 25mg is available in the market in concentration 25mg/Tablet and in the form of Tablets/Film-coated.

ASPEN EUROPE GmbH is the producer of IMURAN 25mg and it is imported from GERMANY, The most popular alternatives of IMURAN 25mg are listed downward .

Mode Of Action

Azathioprine is an imidazolyl derivative of mercaptopurine, which inhibits DNA, RNA and protein synthesis and antagonises purine synthesis. It also inhibits mitosis and interferes with cellular metabolism of susceptible organisms. Azathioprine inj should be converted to oral therapy as soon as the drug can be tolerated.

Indication

Rheumatoid arthritis
Prevention of rejection in organ and tissue transplantation
Auto-immune diseases
Renal homotransplantation

Precaution

Increased risk of serious infections and neoplasia in chronic immunosuppression; leucopenia, thrombocytopenia, renal or hepatic impairment. Increased risk of haematologic toxicity in patients with thiopurine methyltransferase deficiency. Monitor CBC (including platelet count) wkly during 1st mth, twice mthly for 2nd and 3rd mth, then mthly; monitor more frequently if there are dosage adjustments. Monitor LFT periodically; discontinue treatment if jaundice occurs. Reduce dose promptly or withdraw drug temporary if there is rapid decrease/persistently low WBC or signs of bone marrow depression. Dose reduction may be necessary in patients with reduced TPMT (thiopurine methyltransferase) activity. Lactation: Drug excreted at low levels in breast milk; use not recommended

Side Effects

>10% Leukopenia (28-50%)
Infection (20%) <1% Lymphoma Frequency Not Defined Fever
chills; bone marrow depression
thrombocytopenia or anaemia; anorexia
nausea
diarrhoea; arthralgias; secondary infections; hepatotoxicity
rash
alopoecia. Potentially Fatal: Myelosuppression
mutagenicity and carcinogenicity; veno-occlussive liver disease.

Contra indication

Hypersensitivity; previous treatment with alkylating agents; pregnancy, lactation.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Interaction

Increased risk of haematotoxicity with aminosalicylates, drugs that affect myelopoesis e.g. co-trimoxazole or trimethoprim. Increased risk of infections with intra-uterine devices and live vaccines. Increased risk of leucopenia with ACE inhibitors. Concurrent use may reduce the anticoagulant effect of vitamin K antagonists e.g. warfarin. Increased risk of myelosuppressive effects when used with drugs that inhibit TPMT (thiopurine methyltransferase) or xanthine oxidase e.g. olsalazine, allopurinol. Potentially Fatal: Increased risk of serious haematotoxicity or hepatotoxicity with leflunomide. Increased risk of bone marrow suppression with mycophenolate mofetil. Increased risk of infections and malignancies with efalizumab.